Zofenopril evita las alteraciones cardiovasculares en ratones con infusión de Ang II

Referencias bibliográficas

• Ma TK, Kam KK, Yan BP, Lam YY. Reninangiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol. 2010; 160(6):1273-92
• Schiffrin and Touyz. Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade. Journal of the American College of Cardiology. 2003; 42: 911-3
• Cheng et al. Angiotensin II and vascular inflammation Medical Science Monitor. 2005; 11:194-205
• Govender MM, Nadar A. A subpressor dose of angiotensin II elevates blood pressure in a normotensive rat model by oxidative stress. Physiol Res. 2014 Oct 15. [Publicado on line)
• Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res. 2005; 33(1):42-54
• Gómez-Roso M, Montero MJ, Carrón R, Sevilla MA. Cardiovascular changes in spontaneously hypertensive rats are improved by chronic treatment with zofenopril. Br J Pharmacol. 2009; 158(8):1911-21
• Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem. 1981; 112(1):70-75
• Wang HD, Xu S, Johns DG, Du Y, Quinn MT, Cayatte AJ, Cohen RA. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res. 2001; 88(9):947-953
• Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine induced hypertension. Circulation. 1997; 95(3):588-593
• Oktem F, Kirbas A, Armagan A, Kuybulu AE, Yilmaz HR, Ozguner F, Uz E. Lisinopril attenuates renal oxidative injury in L-NAME-induced hypertensive rats. Mol Cell Biochem. 2011; 352(1-2): 247-53